Cardiac Health, Mood, & Neuroimmune Activation
The study is designed to find out more about how mood and the nervous system affect the body's immune system. The investigators plan to study this in people who have been identified by their physician as being at-risk for the development of heart failure. There will be approximately 525 individuals participating in this study at UCSD and at the VASDHS. Individuals who will be asked to take part in this study will have a functional or structural heart problem apparent on an echocardiogram, or a previous heart attack, but no symptoms of heart failure. Some individuals will only complete one assessment (consisting of psychological questionnaires and interview, walk test, blood draw, and body measurements), whereas others deemed "high-risk" on the basis of a laboratory test, will be asked to complete that same assessment every 6 months for the duration of the study.
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||BNP and Neuroimmune Characteristics of CHF and Depression (Competing Renewal)|
- Rate of dysphoria [ Time Frame: up to 4 years ] [ Designated as safety issue: No ]In high-risk (BNP ≥ 65pg/ml) Stage B patients, characterize rates of clinically significant depressed mood (BDI ≥10) and MDD (SCID) and determine prospective relationships with transition to Stages C and/or D HF and clinical outcomes during an average follow-up time of 30 months.
- Neuroimmune activation [ Time Frame: up to 4 years ] [ Designated as safety issue: No ]In high-risk (BNP ≥ 65pg/ml) Stage B patients, characterize the role of neuroimmune activation (defined by circulating levels of C-reactive protein (CRP), Tumor Necrosis Factor-alpha (TNF-α), Interleukin (IL)-6, IL-1β, soluble intercellular adhesion molecule-1 (sICAM-1), soluble P-selectin (sP-selectin), norepinephrine, and functional leukocyte assays)in the relationship between clinically significant depressed mood and/or MDD and transition to symptomatic Stages C and/or D HF and clinical outcomes during an average follow-up time of 30 months.
Biospecimen Retention: Samples With DNA
|Study Start Date:||January 2011|
|Study Completion Date:||February 2015|
|Primary Completion Date:||November 2014 (Final data collection date for primary outcome measure)|
High-risk Stage B Heart Failure Patients
American College of Cardiology/American Heart Association (ACC/AHA) asymptomatic Stage B patients with B-Type natriuretic peptide (BNP) ≥ 65pg/ml
Please refer to this study by its ClinicalTrials.gov identifier: NCT01615094
|Principal Investigator:||Paul J Mills, PhD||University of California, San Diego|